Your browser doesn't support javascript.
loading
Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens.
Srivatsa, Sumana; Montazeri, Hesam; Bianco, Gaia; Coto-Llerena, Mairene; Marinucci, Mattia; Ng, Charlotte K Y; Piscuoglio, Salvatore; Beerenwinkel, Niko.
Afiliação
  • Srivatsa S; Department of Biosystems Science and Engineering, ETH Zurich, 4058, Basel, Switzerland.
  • Montazeri H; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Bianco G; Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
  • Coto-Llerena M; Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel, 4031, Basel, Switzerland.
  • Marinucci M; Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel, 4031, Basel, Switzerland.
  • Ng CKY; Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland.
  • Piscuoglio S; Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel, 4031, Basel, Switzerland.
  • Beerenwinkel N; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Nat Commun ; 13(1): 7748, 2022 12 14.
Article em En | MEDLINE | ID: mdl-36517508
ABSTRACT
The development of cancer therapies is limited by the availability of suitable drug targets. Potential candidate drug targets can be identified based on the concept of synthetic lethality (SL), which refers to pairs of genes for which an aberration in either gene alone is non-lethal, but co-occurrence of the aberrations is lethal to the cell. Here, we present SLIdR (Synthetic Lethal Identification in R), a statistical framework for identifying SL pairs from large-scale perturbation screens. SLIdR successfully predicts SL pairs even with small sample sizes while minimizing the number of false positive targets. We apply SLIdR to Project DRIVE data and find both established and potential pan-cancer and cancer type-specific SL pairs consistent with findings from literature and drug response screening data. We experimentally validate two predicted SL interactions (ARID1A-TEAD1 and AXIN1-URI1) in hepatocellular carcinoma, thus corroborating the ability of SLIdR to identify potential drug targets.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mutações Sintéticas Letais / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mutações Sintéticas Letais / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça